Company Profile
Vivani Medical Stock Price, News & Catalysts
- Ticker:
- VANI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.21 USD (-0.82%)
Close
Last updated: September 17, 2026
112M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, VANI closed down 0.82% at $1.21. No new same-company headline was identified in the current news window.
Company overview
Long-Acting Implant Company
Vivani Medical develops miniature drug implants intended to provide multi-month delivery of established medicines.
NanoPortal Technology
The NanoPortal platform controls drug diffusion through a compact implant, with the goal of improving adherence and reducing treatment burden.
NPM-139
NPM-139 is an ultra-long-acting semaglutide implant for chronic weight management and the lead program in Vivaniās SLIM clinical platform.
Future catalysts
- Topline results from the Phase 1 SLIM-1 study of NPM-139 in November 2026.
- IND submission for NPM-139 to support a Phase 2 obesity study planned for 2027.
- Initiation of the Phase 2 NPM-139 dose-ranging study in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vivani Medical (VANI)?
Vivani Medical (VANI) most recently closed at 1.21 USD, a -0.82% move versus the previous session.
What is the market cap of Vivani Medical (VANI)?
Vivani Medical currently has a market capitalization of 112M USD on BioPharmSignal.
What does Vivani Medical do?
Long-Acting Implant Company Vivani Medical develops miniature drug implants intended to provide multi-month delivery of established medicines. NanoPortal Technology The NanoPortal platform controls drug diffusion through a compact implant, with the goal of improving adherence and reducing treatment burden. NPM-139 NPM-139 is an ultra-long-acting semaglutide...
On which exchange is VANI stock listed?
Vivani Medical (VANI) is associated with NASDAQ, United States, Biopharma.
What is NPM-139?
Topline results from the Phase 1 SLIM-1 study of NPM-139 in November 2026.
Which conditions is Vivani Medical targeting with NPM-139?
Vivani Medical is associated with obesity based on its company overview and current catalyst commentary.
How does Vivani Medical describe recent progress with NPM-139?
Topline results from the Phase 1 SLIM-1 study of NPM-139 in November 2026.
What is SLIM-1?
Topline results from the Phase 1 SLIM-1 study of NPM-139 in November 2026.